Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

• Published in: Cancer science Vol. 109; no. 12; pp. 3993 - 4002
• Main Authors: Kimura, Takayuki, Kato, Yu, Ozawa, Yoichi, Kodama, Kotaro, Ito, Junichi, Ichikawa, Kenji, Yamada, Kazuhiko, Hori, Yusaku, Tabata, Kimiyo, Takase, Kazuma, Matsui, Junji, Funahashi, Yasuhiro, Nomoto, Kenichi
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.12.2018; John Wiley and Sons Inc
• Subjects: Angiogenesis inhibitors; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - pharmacology; Antitumor activity; anti‐PD‐1 antibody; Apoptosis; Cancer therapies; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - immunology; CD8 antigen; CD8-Positive T-Lymphocytes - cytology; CD8-Positive T-Lymphocytes - drug effects; Cell death; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Clinical trials; Enzyme inhibitors; Fibroblast growth factor receptor 1; Hepatocellular carcinoma; Immune checkpoint inhibitors; Immunocompetence; Immunodeficiency; Immunomodulation; immunomodulatory activity; Kinases; Laboratories; lenvatinib; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - immunology; Lymphocytes; Lymphocytes T; Macrophages; Metastasis; Mice; Monoclonal antibodies; Monocytes; Mortality; Original; PD-1 protein; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - pharmacology; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Protein-tyrosine kinase receptors; Quinolines - administration & dosage; Quinolines - pharmacology; Response rates; Ret protein; Ribonucleic acid; RNA; Sequence Analysis, RNA; Single-Cell Analysis; sorafenib; Sorafenib - administration & dosage; Sorafenib - pharmacology; Targeted cancer therapy; Thyroid cancer; Tumors; Vascular endothelial growth factor; Xenograft Model Antitumor Assays; United States > US; China; Japan; anti-PD-1 antibody; lenvatinib; sorafenib; immunomodulatory activity; hepatocellular carcinoma

Angiogenesis inhibitors such as lenvatinib and sorafenib, and an immune checkpoint inhibitor (ICI), nivolumab, are used for anticancer therapies against advanced hepatocellular carcinoma (HCC). Combination treatments comprising angiogenesis inhibitors plus ICIs are promising options for improving cl...